Medicare covers Pluvicto, but only for a specific type of prostate cancer and only after certain other treatments have been tried first.

Pluvicto is a radioactive drug treatment for metastatic castration-resistant prostate cancer — cancer that has spread beyond the prostate and no longer responds to hormone therapy. Medicare Part B covers the drug itself and the infusion procedure when your doctor prescribes it in an outpatient hospital or clinic setting. However, coverage comes with conditions: your cancer must meet specific criteria, and you typically must have received other treatments before Pluvicto becomes an option your doctor will consider.

The coverage decision rests on medical necessity, which means your oncologist must document that Pluvicto is appropriate for your particular cancer stage and history. This is not automatic — your doctor submits the treatment plan, and Medicare reviews it against established clinical guidelines. Understanding what Medicare requires, what you will pay, and how to move forward if your claim is denied can help you prepare for this conversation with your care team.

Key Takeaways

  • Medicare Part B covers Pluvicto infusions at outpatient facilities when prescribed for metastatic castration-resistant prostate cancer that meets specific criteria.
  • Your doctor must document that you have already received other standard treatments, such as chemotherapy or hormone therapy, before Pluvicto is considered medically necessary.
  • You pay 20 percent of the Medicare-approved amount for the infusion after you meet your Part B deductible, which is separate from any drug costs.
  • If Medicare denies coverage, your doctor can request a review, and you have the right to appeal the decision within a set timeframe.
  • Pluvicto is administered as an outpatient infusion, typically once every six weeks, and Medicare covers the procedure at hospitals and certified outpatient clinics.

What Pluvicto Is and How Medicare Evaluates It

Pluvicto (lutetium Lu 177 gozetotide) is a targeted radioactive therapy that attaches to cancer cells and delivers radiation directly to them. It is used only for men whose prostate cancer has metastasized — spread to bones or other organs — and whose cancer no longer responds to standard hormone-blocking drugs. This is called castration-resistant prostate cancer, and it represents an advanced stage where earlier treatments have stopped working.

Medicare evaluates Pluvicto using the same standard it applies to all cancer drugs: the treatment must be reasonable and necessary for the patient's condition. In practice, this means your oncologist must show that you fit the patient population studied in the clinical trials that led to FDA approval. Those trials enrolled men who had already received chemotherapy (usually docetaxel) or other systemic treatments. Medicare's coverage policy reflects this evidence — it covers Pluvicto for men in that situation, not as a first-line treatment.

Medicare Part B Coverage and Your Out-of-Pocket Costs

Medicare Part B covers the Pluvicto infusion procedure itself when it is performed at a hospital outpatient department or a certified outpatient clinic. The drug is considered a Part B drug because it is administered by a healthcare provider, not dispensed for you to take at home. This means your costs are tied to Part B rules, not Part D prescription drug coverage.

After you meet your annual Part B deductible (which varies year to year), you pay 20 percent of the Medicare-approved amount for each infusion. The remaining 80 percent is covered by Medicare. If you have a Medigap or Medicare Advantage plan, your supplemental coverage may reduce or eliminate that 20 percent coinsurance, depending on your specific plan. Pluvicto is typically given once every six weeks, so you will have multiple infusions over the course of treatment. Ask your infusion center to estimate your out-of-pocket cost based on the Medicare-approved amount for your area, as this can vary.

When Medicare Will and Will Not Cover Pluvicto

Medicare covers Pluvicto when all of the following are true: you have metastatic castration-resistant prostate cancer; you have received prior systemic therapy (such as chemotherapy or certain hormone therapies); your doctor documents that Pluvicto is medically necessary for your condition; and the infusion is performed at a Medicare-approved facility. The prior treatment requirement is important — it reflects the clinical evidence and Medicare's policy that Pluvicto is not a first-line drug.

Medicare will not cover Pluvicto if your cancer has not metastasized, if it still responds to hormone therapy, or if you have not received prior systemic treatment. It also will not cover the drug if it is administered in a setting that is not Medicare-approved, such as a private office that does not meet Medicare's facility standards for radioactive drug administration. If your doctor believes Pluvicto is appropriate but your claim is denied, your doctor can request a review, and you can appeal.

How to Prepare for a Pluvicto Treatment Discussion With Your Doctor

Before your oncology appointment, gather your treatment history: the names and dates of all chemotherapy, hormone therapy, and other systemic treatments you have received, and the results of your most recent imaging and blood work. Bring your Medicare card and any supplemental insurance cards. Write down questions about why your doctor thinks Pluvicto is right for you now, what the expected benefits are, what side effects to watch for, and how often you will need infusions.

Ask your doctor's office whether they have submitted similar cases to Medicare and what the typical approval timeline is. Some offices have experience with Pluvicto coverage and can tell you upfront whether your case is likely to be approved. If your doctor recommends Pluvicto, ask them to explain in writing why it meets Medicare's criteria — this documentation is what Medicare will review. If you have a Medicare Advantage plan instead of Original Medicare, ask whether your plan covers Pluvicto, because some plans have different rules than Original Medicare.

What Happens If Medicare Denies Coverage

If Medicare denies your claim, you will receive a notice called an Explanation of Benefits (EOB) that explains the reason. Common reasons for denial include: the claim shows you have not received prior systemic therapy, the facility was not Medicare-approved, or the diagnosis code does not match Medicare's coverage criteria. Your doctor can request a review by submitting additional medical records or clarification about your treatment history.

You also have the right to appeal. The appeal process has multiple levels: first, your doctor can ask Medicare to reconsider; if that is denied, you can request a hearing before a Medicare administrative law judge. Your doctor's office usually handles the first request for reconsideration. If you have a Medigap or Medicare Advantage plan, contact your plan first — they may have their own appeal process or may handle the appeal on your behalf. Keep copies of all correspondence, and note the dates of each step.

Pluvicto at Different Types of Medicare-Approved Facilities

Pluvicto infusions must be given at a facility licensed to handle radioactive materials and approved by Medicare. This includes hospital outpatient departments and independent outpatient clinics that meet Medicare's standards. Not all cancer centers are set up to administer radioactive drugs — the facility must have a nuclear medicine department or a specially trained staff and proper equipment.

If your oncologist recommends Pluvicto but your local cancer center cannot administer it, your doctor can refer you to a facility that can. Medicare will cover the infusion at any Medicare-approved facility, regardless of distance, so you may need to travel for treatment. Ask your doctor which facilities in your region offer Pluvicto and whether they can coordinate your care with your local oncologist. Some large medical centers and academic hospitals are more likely to have the infrastructure for radioactive drug administration.

Frequently Asked Questions

Does Medicare Advantage cover Pluvicto the same way Original Medicare does?

Medicare Advantage plans must cover at least what Original Medicare covers, but some plans may have additional requirements, such as prior authorization or a higher coinsurance. Contact your plan directly to ask whether Pluvicto is covered and what your out-of-pocket cost will be. Your plan's coverage rules may differ from Original Medicare's.

What if I have already had chemotherapy but my doctor says I need Pluvicto before trying another hormone therapy?

Medicare's coverage policy allows for Pluvicto after prior systemic therapy, which includes chemotherapy. If your doctor believes Pluvicto is the right next step based on your cancer's response and your overall health, they can submit that reasoning to Medicare. The key is that you have received prior treatment — the specific sequence may be flexible depending on your medical situation.

Will my Medigap plan cover the 20 percent coinsurance for Pluvicto?

Most Medigap plans cover Part B coinsurance, but the amount depends on your specific plan. Check your Medigap plan documents or call your plan to confirm. If you have Plan G or Plan N, for example, they typically cover the 20 percent coinsurance for Part B services, but you should verify before treatment begins.

How long does it take Medicare to approve Pluvicto?

Approval timelines vary, but many claims are processed within one to two weeks if all required documentation is submitted upfront. Some facilities have experience expediting Pluvicto claims. Ask your infusion center how long approval typically takes in your area so you can plan your treatment schedule accordingly.

Can I get Pluvicto if I am on a clinical trial?

If you are enrolled in a clinical trial, the trial may cover Pluvicto as part of the study, or Medicare may still cover it separately. Ask your trial coordinator and your Medicare plan whether both will cover the treatment or whether one is primary. Coordination between the trial and Medicare can be complex, so clarify this before your first infusion.